Disclosure of Interests: Luciano Lo Giudice: None declared, Maria Laura Acosta Felquer: None declared, Maria Laura Galimberti: None declared, Luis Mazzuocolo: None declared, Enrique Soriano Grant/research support from: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer Inc, Sandoz, Consultant of: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer Inc, Sandoz, Speakers bureau: AbbVie, Amber, Bristol-Myers Squibb, Eli Lilly, Novartis, Pfizer Inc, Roche
DOI: 10.1136/annrheumdis-2020-eular.4805

SAT0427

COMPARATIVE EFFECTIVENESS OF TOFACITINIB (TF) AND ADALIMUMAB (ADA) IN PSORIATIC ARTHRITIS (PSA) PATIENTS IN REAL CLINICAL PRACTICE.

E. Loginova¹, T. Korotaeva¹, E. Gubar¹, Y. Korsakova¹, S. Glukhova¹, E. Vasilenko², A. Vasilenko³, N. Kuznetsova⁴, I. Patrikeeva⁵ on behalf of RU-PsART Study Group. ¹Nasonova Research Institute of Rheumatology, Moscow, Russian Federation; ²St. Petersburg Clinical Rheumatology Hospital No.25, St. Petersburg, Russian Federation; ³Novgorod Regional Clinical Hospital, Novgorod, Russian Federation; ⁴City Clinical Hospital No. 40, Ekaterinburg, Ekaterinburg, Russian Federation; ⁵Tyumen Regional Clinical Hospital No.1, Tyumen, Russian Federation

Background: Tofacitinib (TF) is an oral Janus kinase inhibitor approved for PsA treatment. It has demonstrated comparable to ADA efficacy in RCT in reducing PsA clinical symptoms^{1,2}. There is currently no data concerning comparative effectiveness of TF and ADA in clinical practice. The Russian PsA RegisTry (RU-PsART) collected data from 43 rheumatology centers of the Russian Federation.

Objectives: to study responses to TF or ADA over a period of 6 months (mo) treatment in patients (pts) with active PsA in real clinical practice.

Methods: 77 (M/F=43/34) PsA pts fulfilling the CASPAR criteria from the RU-PsART cohort were divided into two groups according to the treatment given. 41pts (M/F=24 (58.5%)/17 (41.5%), mean age 42.4±10.3 years (yrs), median (Me) PsA duration 72 [35;120] mo were treated with TF 5mg twice daily. 36 pts (M/F=19 (52.8%)/17 (47.2%), mean age 44±11.5 yrs, Me PsA duration 59 [22;102] mo were treated with ADA 40 mg/2 weeks, subcutaneous, as a first-line bDMARD. In TF/ADA groups 89%/52.8% pts accordingly were given combination therapy with Methotrexate (MTX). At baseline (BL) and at 6 mo of therapy PsA activity by DAPSA, BASDAI, the number of pts (Npts) with dactylitis, enthesitis by LEI, BSA, HAQ were evaluated in both groups. At 6 mo of therapy the Npts who achieved remission by DAPSA (≤4)/Low activity (LA)≤14) and Minimal disease activity (MDA, 5 of 7) were calculated in both groups. M±SD, Me [Q25; Q75], Min-Max, %, t-test, Pearson- χ^2 , Mann-Whitney, Wilcoxon tests were performed. All p<0.05, were considered to indicate statistical significance.

Results: At BL TF pts had higher PsA activity by DAPSA compared to ADA group: 44.2[37.8; 55.3]/35.8 [21.1; 52] accordingly (p=0.03). At 6 mo of treatment DAPSA significantly decreased in TF/ADA groups - to 11 [4.3; 17.3]/9.1[6; 19.6] (p<0.001) accordingly. At 6 mo of therapy there were no significant differences between groups in achieving MDA, DAPSA LA/Remission (table 1). At 6 mo of treatment in TF-treated group the Npts with dactylitis significantly decreased from 22 (53.7%) to 5 (13.2%) pts (p<0.001), and in ADA-treated group no significant differences were found in Npts with dactylitis [despite a quantitative decrease from 13 (36.1%) to 6 (20%) pts (p=0.15)]. The Npts with enthesitis in both TF/ADA groups decreased significantly: from 27 (69.2%) to 12 (30.8%) (p<0.002) and from 16 (72.7%) to 5 (38.5%) (p<0.046) pts accordingly. In TF/ADA-treated pts BASDAI improved from 6 [4.2;7] to 1.4 [0.6; 3.2] (p<0.001)/from 4.4 [1.9;5.8] to 3 [0.8;4.5] accordingly (p<0.046); HAQ significantly decreased from 1 [0.625;1.5] to 0.5 [0; 0.875] and from 0.875 [0.5;1.38] to 0.5 [0; 0.875] accordingly. The Npts with BSA>3% significantly reduced in the TF group: from 20 (51.3%) to 8 (26.7%) pts (p<0.002), but not in the ADA group.

Table 1. MDA, DAPSA LA/Remission in TF/ADA at 6 mo

Study	TF		ADA		OR (95% CI)	P
	Events	Subjects	Events	Subjects		
DAPSA remission abs, % achieved	11 (26.8%)	41	6 (20.8%)	29	1.406 (0.453-4.366)	0.556
DAPSA LA abs, % achieved	15 (36.6%)	41	13 (44.8%)	29	0.710 (0.269-1.872)	0.489
MDA abs, % achieved	16 (40%)	40	9 (30%)	30	1.556 (0.569-4.249)	0.389

Conclusion: In real clinical practice TF and ADA demonstrated comparable effectiveness in all clinical domains of active PsA and showed equal result in achievement of MDA/LA/Remission according to DAPSA.

References:

- Mease P, Hall S, FitzGerald O, et al. N Engl J Med 2017;377:1537–50.
- Gladman D, Rigby W, Azevedo VF, et al. N Engl J Med 2017;377:1525–36.

Acknowledgments: no

Disclosure of Interests: Elena Loginova Speakers bureau: Janssen, Tatiana Korotaeva Consultant of: Pfizer, MSD, Novartis, AbbVie, Celgene, JSC BIOCAD, Janssen, UCB, Lilly and Novartis-Sandoz, Speakers bureau: Pfizer, MSD, Novartis, AbbVie, Celgene, JSC BIOCAD, Janssen, UCB, Lilly and Novartis-Sandoz, ELENA GUBAR: None declared, Yulia Korsakova: None declared, Svetlana Glukhova: None declared, Elizaveta Vasilenko: None declared, Aleksey Vasilenko: None declared, Natalia Kuznetsova: None declared, Irina Patrikeeva: None declared
DOI: 10.1136/annrheumdis-2020-eular.1818

SAT0428

IMPACT OF DOSE ESCALATION OF SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL-WORLD SETTING.

M. Martin Lopez¹, B. Joven-Ibáñez¹, J. L. Pablos¹. ¹Hospital Universitario 12 de Octubre, Madrid, Spain

Background: Secukinumab (SEC) has provided efficacy in clinical trials in patients with psoriatic arthritis (PsA). In PsA patients, a gain in response has been suggested by dose escalation from 150 to 300 mg in the open phase of the FUTURE study¹.

Objectives: To analyze the usefulness of dose escalation of SEC from 150 to 300 in patients with non-responding PsA to 150 mg in real-world setting.

Methods: Multicentric observational, longitudinal, retrospective study conducted in a tertiary hospital between January 2016 and December 2019. Patients with PsA (CASPAR criteria) receiving at least one dose of SEC were included. Medical records were reviewed to collect demographic and clinical data related to PsA (including activity assessment and treatment). Descriptive statistics and a comparative analysis of the efficacy of SCK by the Student t test in the different dose groups and by the ANOVA test to compare the response between the three dose groups were performed.

Results: 98 patients with PsA treated with SEC, of which 69(70%) female were included. Mean age was 54 y.o (SD12) and average duration of the disease was 9 (SD 7) years. Three groups were made according to the dose received, SEC150, SEC300 and SEC150-300 (non-responders after SEC150 onset increasing to 300 mg). The SEC150 group includes 58(59%) patients of whom 32(55%) had received at least one biological (16 one biological, 8 two biological and 10 three or more). The survival of SEC was 1.3 (SD1) years and was suspended in 24(41%) patients, due to primary failure in 9, secondary failure 10, adverse events 4 and allergy to latex 1. The SEC300 group includes 12 (12%) patients of whom 10 (83%) had received at least one biological (1 one biological, 3 two and 6 three or more). The survival of the SEC was 1.6 SD (1.3) years and was suspended in 8 (67%) patients, due to primary failure in 2, secondary failure 5 and remission 1. Finally, the SEC150-300 group includes 28 (29%) patients of whom 17 (61%) had received at least one biologic (7 one biologic, 2 two and 8 three or more). The survival of the SEC was 1.6 (SD0.9) years and was suspended in 13 (46%) patients, all due to secondary failure. 54%, therefore, maintains the SCK after responding to the dose increase. The average time of dose increase to 300 mg was 9(SD6) months. In the three treatment groups, a significant decrease in the values of CRP, ASDAS-CRP and DAPSA was observed at 6 months of SEC (Table 1). However, when comparing the difference of means obtained during follow-up (Δ CRP, Δ ASDAS and Δ DAPSA) between the 3 dose groups, no significant differences were found (p=0.76 for CRP, p=0.86 for ASDAS and p=0.35 for DAPSA).

Table 1. Disease activity assessment at 6 months of SEC therapy.

	Baseline	6 months after SEC	Mean difference	p value
CRP300 (mg/L)	9±8,3	4,7±3,7	-4,3 (IC95% -8,9 a 0,2)	p=0,06
CRP150 (mg/L)	7,3±9,1	4,0±4,7	-2,9 (IC95% -4,7 a -1,3)	p=0,0009
CRP150-300(mg/L)	9,9±11	6,0±7,4	-3,9 (IC95% -6,9 a -0,5)	p=0,0142
ASDAS-CRP300	2,3±0,7	1,6±0,6	-0,6 (IC95% -0,9 a -0,3)	p=0,0014
ASDAS-CRP150	2,3±0,6	1,6±0,7	-0,7 (IC95% -0,8 a -0,5)	p<0,0001
ASDAS-CRP150-300	2,2±0,6	1,6±0,7	-0,6 (IC95% -0,8 a -0,4)	p<0,0001
DAPSA300	33,7±19,3	16,9±10,6	-16,8 (IC95% -29,6 a -3,9)	p=0,01
DAPSA150	27,4±11,4	15,4±10,4	-11 (IC95% -14,4 a -7,6)	p<0,0001
DAPSA150-300	28±9,9	15,8±8,7	-12,2 (IC95% -15,3 a -9,1)	p<0,0001

CRP300: C-reactive protein in patients with SCK 300 mg, CRP150: in patients with SCK 150, CRP150-300: in patients with dose escalation from 150 to 300 (same for ASDAS-CRP and DAPSA), SEC: secukinumab

Conclusion: There are no significant differences in the response evaluated by CRP, ASDAS-CRP and DAPSA between the dose of 150 and 300 mg of SEC. However, both doses of treatment provided efficacy in clinical practice with significant reduction of activity parameters. In the case of patients not responding to SEC150 mg and prior failure to TNFi, increasing the dose to 300 mg could be an effective option.

References:

[1] Mease PJ, et al. ACR Open Rheum.2020 Jan;2(1):18-25.

Disclosure of Interests: MARIA MARTIN LOPEZ: None declared, Beatriz Joven-Ibáñez Speakers bureau: Abbvie, Celgene, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, José Luis Pablos: None declared

DOI: 10.1136/annrheumdis-2020-eular.6579

SAT0429

SECUKINUMAB IMPROVES CLINICAL AND PATIENT-REPORTED OUTCOMES AT 6 MONTHS AMONG PATIENTS WITH PSORIATIC ARTHRITIS IN THE US-BASED CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/SPA) REGISTRY

P. J. Mease¹, T. Blachley², M. Glynn², B. Dube², R. Mclean², N. Kim^{3,4}, P. Hur⁵, A. Ogdie⁶. ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, United States of America; ²Corrona, LLC, Waltham, United States of America; ³Baylor Scott and White Health, Temple, United States of America; ⁴The University of Texas at Austin, Austin, United States of America; ⁵Novartis Pharmaceuticals Corporation, East Hanover, United States of America; ⁶University of Pennsylvania School of Medicine, Philadelphia, United States of America

Background: Secukinumab, an interleukin-17 antagonist approved for the treatment of PsA, improves all PsA manifestations in the GRAPPA-OMERACT core domain set.¹ Few US-based studies have evaluated the real-world effectiveness of secukinumab in patients with PsA.

Objectives: To examine clinical and patient-reported outcomes (PROs) in patients with PsA enrolled in the Corrona PsA/SpA registry initiating secukinumab with ≥ 1 follow-up visit.

Methods: Included were adult patients with PsA in the Corrona registry who initiated secukinumab after April 1, 2017 and remained on secukinumab at their 6-month (window, 5-8 months) follow-up visit. The primary outcome was achievement of minimal disease activity (MDA) at 6 months among patients not in MDA at secukinumab initiation. MDA was defined as meeting 5 of the 7 following criteria: tender joint count (TJC) ≤ 1, swollen joint count (SJC) ≤ 1, psoriasis affected body surface area (BSA) < 3%, patient assessment of pain on visual analog scale (VAS) ≤ 15, patient global assessment VAS ≤ 20, HAQ-DI ≤ 0.5, and tender entheses points ≤ 1 using the Leeds Enthesitis Index (LEI). Secondary outcomes included the proportion of patients who achieved resolution (0 sites) of TJC, SJC, enthesitis (using the LEI), and dactylitis among those with ≥ 1 site at initiation and improvement from baseline in clinical outcomes (BSA, nail psoriasis, physician global assessment, TJC, SJC, and DAPSA) and PROs (patient-reported pain, patient global assessment, HAQ-DI, and Work Productivity and Activity Impairment questionnaire) at 6 months. Outcomes were evaluated in the overall population and in potentially recalcitrant patients with failure of or intolerance to ≥ 3 previous biologics to examine if the later line biologic could be adequately effective.

Results: A total of 100 patients with PsA who initiated and maintained secukinumab after 6 months were included. The mean (SD) age was 51.6 (11.6) years, 54.3% were male, and 96.8% were white. The mean (SD) symptom and disease duration were 10.8 (9.7) and 7.0 (7.0) years, respectively. Thirty patients (30.0%) initiated secukinumab 150mg and 70 (70.0%) initiated secukinumab 300mg. Most (83.0%) were biologic experienced; 17 patients initiated secukinumab as a 1st biologic, 34 as 2nd, 26 as 3rd, and 23 as ≥ 4th. At initiation, 75/90 patients (83.3%) were not in MDA; 26/71 (36.6%) of those with follow-up data available achieved MDA at 6 months (Figure 1). In the overall population, 28 patients (41.2%) with TJC ≥ 1, 24 (44.4%) with SJC ≥ 1, 17 (60.7%) with enthesitis, and 9 (75.0%) with dactylitis at initiation achieved resolution at 6 months (Table 1). Improvement was observed at 6 months in clinical outcomes and PROs in the overall population (Figures 1 and 2) and in patients who initiated secukinumab as a ≥ 4th-line biologic.

Table 1. Resolution of Peripheral Arthritis, Enthesitis, and Dactylitis at 6 Months Among Patients With ≥ 1 Site at Initiation

Secondary Outcomes	Initiation, Mean (SD) [n]	6-Month Follow-Up, Resolution (Count = 0), n (%)
TJC (1-68)	9.0 (9.7) [68]	28 (41.2)
SJC (1-66)	4.7 (4.2) [54]	24 (44.4)
Enthesitis (1-6)	1.9 (1.1) [28]	17 (60.7)
Dactylitis (1-20)	2.1 (1.3) [12]	9 (75.0)

Figure 1. Achievement of MDA and Change From Initiation in Clinical Outcomes at the 6-Month Follow-Up for Patients With PsA Who Initiated and Maintained Secukinumab

Figure 2. Change From Initiation in Patient-Reported Outcomes at the 6-Month Follow-Up for Patients With PsA Who Initiated and Maintained Secukinumab

Conclusion: In the Corrona registry, most secukinumab initiators with PsA were biologic experienced and were not in MDA at time of initiation. Consistent with clinical trials, real-world patients treated with secukinumab achieved MDA as well as improvement in clinical manifestations, PROs, and work productivity.

References:

[1] Orbai AM, et al. *J Rheumatol*. 2019 Oct 15. [Epub ahead of print].

Disclosure of Interests: Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau, Taylor Blachley Employee of: Corrona, LLC, Meghan Glynn Shareholder of: Corrona, LLC – shareholder, Grant/research support from: Pfizer – grant/research support, Employee of: Corrona, LLC – employment, Blessing Dube Employee of: Corrona, LLC, Robert McLean Employee of: Corrona, LLC, Nina Kim Employee of: Postdoctoral fellow at the University of Texas at Austin and Baylor Scott and White Health, providing services to Novartis Pharmaceuticals Corporation, Peter Hur Employee of: Novartis Pharmaceuticals Corporation, Alexis Ogdie Grant/research support from: Pfizer to Penn, Novartis to Penn, Amgen to Forward/NDB, Consultant of: Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Corrona, Janssen, Eli Lilly, Novartis, Pfizer

DOI: 10.1136/annrheumdis-2020-eular.1014

SAT0430

SECUKINUMAB EFFECTIVENESS IN 1543 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CLINICAL PRACTICE IN 13 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION NETWORK

B. Michelsen¹, S. Georgiadis¹, D. Di Giuseppe¹, A. G. Loft¹, M. Nissen¹, F. Iannone¹, M. Pombo-Suarez¹, H. Mann¹, Z. Rotar¹, K. Eklund¹, T. K. Kvien¹, M. J. Santos¹, B. Gudbjornsson¹, C. Codreanu¹, S. Yilmaz¹, J. K. Wallman¹, C. H. Brahe¹, B. Moeller¹, E. G. Favalli¹, C. Sanchez-Piedra¹, L. Nekvindova¹, M. Tomsic¹, N. Trokovic¹, E. Kristianslund¹, H. Santos¹, T. Love¹, R. Ionescu¹, Y. Pehlivan¹, G. T. Jones¹, I. Van der Horst-Bruinsma¹, L. Midtbøll Ørnbjerg¹, M. Østergaard¹, M. L. Hetland¹. ¹EuroSpA Research Collaboration Network, Copenhagen, Denmark

Background: There is a lack of real-life evidence on secukinumab effectiveness in psoriatic arthritis (PsA) patients.